Skip to main content
Home > SciBX > Targets & Mechanisms

Chronological Index of SciBX: The Science-Business eXchange: Targets & Mechanisms

SciBX: The Science-Business eXchange Current Issue
  • Raising the Ras inhibitor bar

    About a year after U.S. researchers developed small molecule inhibitors of the intractable target wild-type Ras, a Japanese team has identified compounds that hit Ras mutant tumors in mice. The team now is trying to …

    Published on 5/16/2013
  • Table 1: Alzheimer's disease vaccine pipeline

    Targets & Mechanisms: AD vaccine redux Table 1. Alzheimer's disease vaccine pipeline. At least seven vaccines against b-amyloid (Ab) are in preclinical through Phase II testing to prevent AD. Source: BCIQ: …

    Published on 5/9/2013
  • AD vaccine redux

    Researchers at Harvard have teamed up with Mercia to design a next-generation Alzheimer's disease vaccine. The beta-amyloid-targeted formulation features an adjuvant that promotes a beneficial anti-inflammatory response…

    Published on 5/9/2013
  • Add radioactivity to the Listeria

    An Albert Einstein College of Medicine team has used radiolabeled Listeria monocytogenes to treat metastatic pancreatic cancer in mice. Future studies could involve comparing or combining the strategy with existing …

    Published on 5/2/2013
  • FGFR allosteric inhibition

    Sanofi and Flanders Institute for Biotechnology researchers have discovered a molecule that inhibits FGFR allosterically instead of orthosterically. The pharma is developing analogs of the inhibitor for cancer.

    Published on 5/2/2013
  • Figure 1: Downstream of MERTK

    Targets & Mechanisms: MERTK: upstream from BRAF Figure 1. Downstream of MERTK. According to a study in The Journal of Clinical Investigation, inhibiting c-Mer proto-oncogene tyrosine kinase (MERTK)-which lies …

    Published on 4/25/2013
  • Interfering with interferon

    Separate teams at the Scripps Research Institute and UCLA have shown that blocking type I interferon can resolve viral infections in mice. The findings suggest that interferon treatment of viral infections, although …

    Published on 4/25/2013
  • MERTK: upstream from BRAF

    U.S. researchers have shown that inhibiting c-Mer proto-oncogene tyrosine kinase, a protein that sits upstream from BRAF, reduced melanoma growth in mice. Future studies will need to determine whether inhibitors of this…

    Published on 4/25/2013
  • Oncometabolite takedown

    Agios has reported the first mutant-selective inhibitors of the metabolic enzymes IDH1 and IDH2 and has shown therapeutic effect in preclinical cancer models. The company has a partnership with Foundation Medicine to …

    Published on 4/11/2013
  • RaPID results

    A Japanese team has provided new structural insights into the function of a conserved class of drug transporters. The researchers are collaborating with PeptiDream to develop cyclic peptide inhibitors that hit medically…

    Published on 4/11/2013
  • Figure 1: Glutamine metabolism

    Glutamine metabolism drives PDAC Figure 1. Glutamine metabolism. Cancer cells are dependent on specific metabolic pathways, such as glutamine metabolism, to supply excess energy that sustains cell growth and …

    Published on 4/4/2013
  • Glutamine metabolism drives PDAC

    Dana-Farber researchers have identified a glutamine metabolism pathway activated by oncogenic K-Ras in pancreatic cancers. The team found three different enzyme targets within the pathway that could be targeted to …

    Published on 4/4/2013
  • Proteoglycans on the knee

    Baylor College of Medicine researchers have shown that delivering the gene for proteoglycan 4 to the knee prevented and treated osteoarthritis in mice. GeneQuine has exclusively licensed the findings and is developing a…

    Published on 4/4/2013
  • mAb attack on WT1

    Researchers at Eureka Therapeutics and Memorial Sloan-Kettering have targeted Wilms tumor 1-positive cancer cells with a mAb against peptide fragments derived from the protein that are presented on the cells' surface. …

    Published on 3/28/2013
  • SMAD men

    University of Colorado researchers have shown that topical application of the signaling protein Smad7 can treat and prevent oral mucositis in mice. The team will now test the compound in mice with cancer-associated …

    Published on 3/28/2013
  • Trapping influenza neuraminidase

    A team from The University of British Columbia has used a mechanism-based approach to design irreversible inhibitors of influenza virus neuraminidase. The compounds are being developed by the venture arm of The Centre …

    Published on 3/21/2013
  • Understanding fibrosis

    Researchers from The University of Alabama at Birmingham have shown a therapeutic effect of Rho kinase inhibitors in idiopathic pulmonary fibrosis. Although the results suggest a repurposing opportunity for the …

    Published on 3/21/2013
  • Figure 1: Myofibroblast dynamics

    Understanding fibrosis Figure 1. Myofibroblast dynamics. Lung fibroblasts undergo actin cytoskeleton and actomyosin contractile system remodeling in response to biomechanical and biochemical stimuli. This remodeling …

    Published on 3/21/2013
  • Table 1: TGFB1 and Rho kinase inhibitors

    Understanding fibrosis Table 1. TGFB1 and Rho kinase inhibitors. Transforming growth factor-b1 (TGFB1) inhibitors Company Product Disease category Indication Development InterMune Inc. (NASDAQ:ITMN) Esbriet …

    Published on 3/21/2013
  • Figure 1: WNT signaling in cancer

    Targets & Mechanisms: Placing kinases in the WNT pathway Figure 1. WNT signaling in cancer. A Boston-based team and a Genentech Inc.-led team have each identified a new kinase-v-yes-1 Yamaguchi sarcoma viral oncogene…

    Published on 3/14/2013
  • Placing kinases in the WNT pathway

    A Boston-based team and a group led by Roche's Genentech unit have each identified new kinase regulators of WNT signaling-YES1 and RIPK4, respectively-that provide two new, druggable targets. Each team will now look for…

    Published on 3/14/2013
  • ALL emerges from relapse

    Separate teams from New York University and Columbia University have identified mutations in NT5C2 that predict relapse, drug resistance and poor prognosis in ALL. Inhibiting the enzyme could help sensitize some …

    Published on 3/7/2013
  • Islet transplants find the adrenal gland

    German and U.S. researchers have shown that intra-adrenal transplantation of islet cells preconditioned with an improved peptide agonist of GHRH may normalize glucose levels in diabetic mice better than existing …

    Published on 2/28/2013
  • Making TRAIL

    Researchers at the Penn State Milton S. Hershey Medical Center have identified a small molecule inducer of TRAIL expression that has antitumor effects in multiple mouse models. Oncoceutics has licensed the findings and …

    Published on 2/28/2013
  • Huperzine A in SCI

    Harvard Medical School researchers have shown that the plant-derived small molecule huperzine A can reduce neuropathic pain in mice with spinal cord injury. Insero Health has licensed IP covering epilepsy and …

    Published on 2/21/2013

< Previous   1  2  3  4  5  Next >
Subscribe Now
Free Trial

About BioCentury

Decision-shaping business intelligence for the global biotech and pharma industry since 1993

Log In


Forgot password  |  Forgot Login


If you are a subscriber, but have forgotten or never received a password, please click above to receive a new one.

SciBX: Science-Business eXchange

BioCentury's weekly translational science journal, published in collaboration with Nature Publishing Group:

  • Selects from hundreds of scientific papers published each week to identify early opportunities for investment, alliances and partnerships
  • Reports on the most commercially relevant developments